News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SYGNIS Pharma AG Capital Increase Oversubscribed At Final Closing



12/18/2013 1:31:50 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Madrid, Spain and Heidelberg, Germany, December 18, 2013 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03, Prime Standard) today announced that the Company successfully placed the remaining shares and ultimately closed the share capital transaction announced on October 2nd, 2013. Including the placement of this second tranche, which was considerably oversubscribed, the Company's share capital increases from ? 9,364,258.00 to ? 10,534,790.00 by issuing a total of 1,170,532 new shares against cash contribution resolved by the Management Board of SYGNIS with the approval of the Supervisory Board.

The offering utilizes existing authorized capital created by resolution at the Annual General Meeting on August 28, 2013. The new shares carry full dividend rights as of January 1, 2013. SYGNIS plans to use the gross proceeds of all in all EUR 3.1 million to finance its operating business and further growth.

"We are very proud of the commitment of our shareholders and want to thank them for their ongoing trust in the Company's future opportunities," stated Pilar de la Huerta, CEO of SYGNIS AG. "As a key player in the fast growing market of DNA amplification and sequencing, we are facing an exciting 2014 with the first products entering the markets based on our proprietary core technology QualiPhi® from the agreement with QIAGEN, the world leading provider of sample and assay technologies. In addition, our full pipeline of highly innovative products in next generation sequencing and molecular interaction makes us a perfect partner for key players in drug development, molecular diagnostics and personalized healthcare. The contemplated transaction in our view is in the best interest of the Company and its shareholders as it provides the Company with the financial flexibility to execute on our business strategy."

For further information please contact:
SYGNIS AG
Pilar de la Huerta, CEO/CFO
Tel: +34-918063089
Email: pdelahuerta@sygnis.es:mailto:pdelahuerta@sygnis.es

About SYGNIS AG: www.sygnis.com: http://www.sygnis.com

After the merger in 2012 between X-Pol Biotech, specialising in DNA amplification and sequencing, and SYGNIS AG, listed in the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS' new mission is to develop and distribute technologies and products from X-Pol, which has a commercial product in the DNA amplification segment, QualiPhi® and is currently developing other products in the field of Next Generation Sequencing.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES